Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term oncology-group. Found 16 abstracts

Mackay HJ, Buckanovich RJ, Hirte H, Correa R, Hoskins P, Biagi J, Martin LP, Fleming GF, Morgan R, Wang L, Polintan R, Oza AM. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Gynecologic Oncology. 2012 Apr;125(1):136-40.   PMCID: pmc3303987
Wang SZ, Astsaturov IA, Bingham CA, McCarthy KM, von Mehren M, Xu W, Alpaugh RK, Tang Y, Littlefield BA, Hawkins LD, Ishizaka ST, Weiner LM. Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer Immunology Immunotherapy. 2012 Jan;61(1):49-61.   PMCID: PMC3517883
Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ. A phase II, single-arm study of the anti-alpha 5 beta 1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecologic Oncology. 2011 May;121(2):273-9.   PMCID: not NIH funded
McDonald MW, Lawson J, Garg MK, Quon H, Ridge JA, Saba N, Salama JK, Smith RV, Yeung AR, Yom SS, Beitler JJ, Expert Panel Radiation O. ACR APPROPRIATENESS CRITERIA (R) RETREATMENT OF RECURRENT HEAD AND NECK CANCER AFTER PRIOR DEFINITIVE RADIATION. International Journal of Radiation Oncology Biology Physics. 2011 Aug;80(5):1292-8.   PMCID: not NIH funded
O'Donnell MR, Appelbaum FR, Baer MR, Carabasi MH, Coutre SE, Erba HP, Estey E, Glenn MJ, Kraut EH, Maslak P, Millenson M, Miller CB, Saba HI, Stone R, Tallman MS. NCCN Practice Guidelines for acute myelogenous leukemia. Oncology-New York. 2000 Nov;14(11A):53-61.
Ozols RF. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Seminars in Oncology. 1999 Feb;26(1):84-9.
Langer CJ, Schaebler D, Sauter E, DeMaria D, Johnson C, Reilly DM, Clark J, Leighton J, Aks C, Litwin S, Ridge JA. Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 1998 Aug;20(5):385-91.
Langer CJ, Movsas B, Hudes R, Schol J, Keenan E, Kilpatrick D, Yeung C, Curran W. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: Report of Fox Chase Cancer Center Study 94-001. Seminars in Oncology. 1997 Aug;24(4):89-95.
Ozols RF. Paclitaxel (Taxol(R)) plus carboplatin as first-line treatment for advanced ovarian cancer. International Journal of Gynecological Cancer. 1996 Jan;6:9-12.
Ozols RF. Current Status of Chemotherapy for Ovarian-Cancer. Seminars in Oncology. 1995 Oct;22(5):61-6.
Ozols RF. Treatment of Ovarian-Cancer - Current Status. Seminars in Oncology. 1994 Apr;21(2):1-9.
Ozols RF. Epithelial Ovarian-Cancer - an Update. Bulletin Du Cancer. 1993 Nov;80(11):955-70.
Coia LR. The Role of Radiation-Therapy in the Treatment of Brain Metastases. International Journal of Radiation Oncology Biology Physics. 1992 Jan;23(1):229-38.
Comis RL. Developments in Therapy for Extensive-Disease Small-Cell Lung- Cancer. Seminars in Oncology. 1992 Dec;19(6):45-50.
Ozols RF. Advances in the Chemotherapy of Gynecologic Malignancies. Hematological Oncology. 1992 Jan;10(1):43-51.
Odwyer PJ, Langer CJ, Walczak J, Levy MH, Padavicshaller K, Hudes GR, Litwin S, Comis RL. Phase-Ii Study of Weekly 5-Fluorouracil, Cisplatin and Vinblastine in Advanced Non-Small-Cell Lung-Cancer. European Journal of Cancer. 1991 Dec;27(12):1589-93.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term oncology-group

oncology-group cisplatin randomized trial chemotherapy carcinoma cyclophosphamide carboplatin phase-iii phase-i infusion therapy stage-iii taxol trial ovarian cancer intraperitoneal therapy squamous-cell carcinoma survival angiogenesis radiotherapy hyperfractionated radiation-therapy first remission laparotomy dose cell lung-cancer soft-tissue sarcomas uterus vindesine alpha 5 beta 1 integrin irradiation efficacy combination chemotherapy brain metastases regimens external beam irradiation N-phosphonacetyl-L-aspartate high-dose cytarabine Toll-like receptor 4 agonist Trap) p53 altered marrow transplantation liposomal induction chemotherapy doxorubicin induction concurrent chemotherapy combination central nervous-system advanced squamous cell carcinoma of the arsenic trioxide Phase II dna- nasopharyngeal carcinoma cyto-toxicity bone- Carcinosarcoma anti-cd20 monoclonal-antibody prognostic-factors transgenic mice fractionation regimen in cranial irradiation paclitaxel multidrug resistance randomized-trial gemcitabine plus alpha(5)beta(1) integrin mixed mullerian tumors stereotaxic cancer immunotherapy acute promyelocytic leukemia bevacizumab ifosfamide cis-platinum cervical-cancer recombinant interferon alpha linear-accelerator mesna drug resistance Transgenic mouse intraperitoneal cisplatin single-agent Appropriateness criteria salvage surgery bronchogenic-carcinoma docetaxel Platinum resistant fibronectin 5-fluorouracil HER2 ovarian-cancer randomized 1st 2 complications of cranial irradiation intensive weekly chemotherapy fc-gamma-ri cisplatin plus cyclophosphamide fluorouracil Antibody therapy 2nd primary head adenocarcinoma repair Volociximab metastatic breast-cancer 2nd-look alternating postoperative reirradiation endothelial growth-factor cerebral metastases Head-and-neck cancer Ovarian cancer Uterine leiomyosarcoma low-dose paclitaxel surgery methotrexate Antitumor immunity head and neck leucovorin fluorouracil infusion intraperitoneal chemotherapy high-dose etoposide dose intensity Reirradiation receptor agonists lymphoma Aflibercept (VEGF overexpression malignant-melanoma circulating tumor-cells Salvage 3-hour acute myeloid-leukemia cytoreductive
Last updated on Wednesday, February 05, 2020